Skip to main content
Veterinary Medicines

KALAFEV, 50 mg/ml, ενέσιμο διάλυμα για βοοειδή, χοίρους και άλογα

Authorised
  • Flunixin meglumine

Identifikazzjoni tal-prodott

Isem tal-mediċina:
KALAFEV, 50 mg/ml, ενέσιμο διάλυμα για βοοειδή, χοίρους και άλογα
Sustanza attiva:
Metodu ta’ amministrazzjoni:
  • Użu għal ġol-muskoli
  • Użu għal ġol-vini

Dettalji tal-prodott

Sustanza attiva / Qawwa:
  • Disponibbli biss fi English
    82.95
    milligram(s)
    /
    1.00
    millilitre(s)
Forma farmaċewtika:
  • Soluzzjoni għall-injezzjoni
Withdrawal period by route of administration:
  • Intramuscular use
    • Cattle
      • Meat and offal
        10
        day
      • Milk
        24
        hour
    • Horse
      • Meat and offal
        7
        day
    • Pig
      • Meat and offal
        18
        day
  • Intravenous use
    • Cattle
      • Meat and offal
        10
        day
      • Milk
        24
        hour
    • Horse
      • Meat and offal
        7
        day
    • Pig
      • Meat and offal
        18
        day
Kodiċi veterinarju anatomiku terapewtiku kimiku (ATCvet):
  • QM01AG90
Status tal-awtorizzazzjoni:
  • Valid
Authorised in:
  • Greece
Available in:
  • Greece
Deskrizzjoni tal-pakkett:

Tagħrif addizzjonali

Entitlement type:
Id-detentur tal-awtorizzazzjoni għat-tqegħid fis-suq:
  • Fatro S.p.A.
Marketing authorisation date:
Siti ta’ manifattura b’rilaxx tal-lott:
  • Fatro S.p.A.
Awtorità responsabbli:
  • National Organization For Medicines
Numru tal-awtorizzazzjoni:
  • 69428/18/26-11-2019/K-0186601
Data tal-bidla fl-istatus tal-awtorizzazzjoni:

Dokumenti

Sommarju tal-karatteristiċi tal-prodott

Dan id-dokument ma jeżistix f'dan il-lingwa (Malti). Tista 'ssibha f'lingwa oħra hawn taħt.
Greek (PDF)
Ippubblikat fuq: 20/06/2022
How useful was this page?:
No votes yet
"Please do not include any personal data, such as your name or contact details. If you do, you consent to the processing of that data in accordance with EMA’s Privacy Statement concerning requests for information or access to documents. If you would like a reply from EMA, please Send a question to EMA instead."